Brokerage : Daishin Securities
Analyst : Kahye Hong (RA: Chaeri Lee)
Investment Rating : BUY (Initiation)
Target Price : KRW 2,000,000 (Initiation)
Core Momentum : Operating leverage maximization driven by Plant 5 full operation and US plant revenue integration, complemented by medium-to-long-term growth engines including Plant 6 construction and ADC modality expansion.
📊 1. [Valuation & Key Financial Metrics]
- Rating & Target Price: BUY (Initiation) / Target Price KRW 2,000,000 (Derived via DCF methodology covering 2026–2033, applying WACC of 7.8% and terminal growth rate of 3.5%; upside potential of 39% based on the May 19, 2026 closing price of KRW 1,346,000)
- Market Data: Market Cap KRW 62.31 Trillion / Capital Stock KRW 116.0 Billion / Foreign Ownership 12.20% / Major Shareholders: Samsung C&T and 5 affiliates 74.31%, National Pension Service 6.68%
- Annual Financial Forecast (Daishin Securities Estimates):
- 2026F: Revenue KRW 5.69 Trillion, Operating Profit KRW 2.56 Trillion, Pre-tax Profit KRW 2.60 Trillion, Net Profit (Controlling) KRW 1.95 Trillion, EPS KRW 42,113, BPS KRW 265,948, PER 32.9x, PBR 5.2x, ROE 19.7%
- 2027F: Revenue KRW 6.70 Trillion, Operating Profit KRW 3.08 Trillion, Pre-tax Profit KRW 3.11 Trillion, Net Profit (Controlling) KRW 2.33 Trillion, EPS KRW 50,304, BPS KRW 316,303, PER 27.6x, PBR 4.4x, ROE 17.3%
- 2028F: Revenue KRW 6.90 Trillion, Operating Profit KRW 3.24 Trillion, Pre-tax Profit KRW 3.26 Trillion, Net Profit (Controlling) KRW 2.45 Trillion, EPS KRW 52,855, BPS KRW 369,201, PER 26.2x, PBR 3.8x, ROE 15.4%
🚀 2. [Market Opportunities & Business Outlook]
- Earnings Visibility & Operating Leverage Phase:
- Downside risk is strongly protected by long-term customer lock-in structures and minimum purchase commitment contracts as the world’s largest antibody CDMO.
- High profitability is sustained through economies of scale, with the 2026F operating profit margin estimated at ~45%.
- Following initial revenue recognition from the US site and rising utilization at Plant 5 in 2026, fixed-cost operating leverage is expected to reach full scale once Plant 5 operates at 100% capacity in 2027.
- Medium-to-Long-Term Growth Catalysts & Diversification:
- Groundbreaking of Plant 6 within the year will reinforce medium-to-long-term manufacturing growth momentum.
- Parallel expansion via the US GSK facility acquisition and entry into ADC (Antibody-Drug Conjugates) modalities will drive geographical and technological diversification.
- Near-Term Risk Factors & Entry Opportunity:
- While short-term production disruptions from labor strike negotiations present temporary operational variance (not incorporated into baseline estimates), visible large-scale contract wins are expected to serve as the primary catalyst to resolve market overhang.
📝 Editor’s Comment (Perspective)
The analyst views Samsung Biologics not merely as a high-capacity contract manufacturer, but as a compound growth enterprise leveraging global-scale leadership and rigid long-term contract structures to convert capacity expansions directly into structural operating leverage. The core perspective prioritizes the qualitative margin inflection driven by Plant 5’s full commercialization and global asset integration over transient operational noise stemming from labor discussions.
To verify whether this investment thesis progresses as expected, investors should primarily monitor the actual top-line contribution from the US facility in the second half of 2026, the margin expansion trajectory toward full utilization of Plant 5 in 2027, the formal groundbreaking milestone for Plant 6, and disclosures of major new CDMO contract wins. These developments can be verified through future quarterly earnings releases, official company IR presentations, and regulatory filings on DART/KRX.
📢 Disclaimer & Source
Source: This content has been structured and newly written based on officially disclosed financial facts and data from brokerage reports.
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific securities. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: Compliance and Copyright Inquiries (ksb220805@gmail.com)
